Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

This article was originally published in Scrip

Executive Summary

Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion Inc. and Pfizer Inc. said they won't put it on the market until after June 29.


Related Content

Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Pfizer/Celltrion Prep For October Inflectra Launch
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi
Pfizer Split, Once Decided, Could Happen Quickly, CEO Says
Stockwatch: No Earnings Disappointments Are The New Black





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts